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Calculation skills: Cardiovascular Disease                                                                        
Cardiovascular disease (CVD) accounts for approximately one third of deaths in England and Wales, 
with the associated morbidity costing the NHS in England alone almost 8 million pounds in 2010 (NICE, 
2014). Modifiable risk factors include hypertension, smoking and raised cholesterol levels. As such, 
the Joint Formulary Committee (2016) identify that preventative measures, through the use of lipid-
regulating drugs, should be taken where there is a high risk of developing CVD and to prevent 
recurrence in those with recognised CVD.  
 
Question 1 
Sanjay is 54 years old and works as an administrator. He has diabetes and although adherent to his 
management plan, he is unable to exercise due to joint pain. He has been assessed using the QRISK2 
risk assessment tool and has been identified at 19% risk of having a heart attack or stroke in the next 
10 years. 
(i) Out of a crowd of 1000 people with the same risk factors as Sanjay, how many are likely to have a 
heart attack or stroke in the next 10 years? 
(ii) Sanjay is prescribed atorvastatin 20mg daily. Atorvastatin 20mg tablets are available in packs of 28 
(£24.64) and 90 (£79.20). What would be the most cost effective way (without splitting packs) to 
prescribe the treatment from 1st June to 30th November?   
Question 2  
In 2010, 180,000 deaths in England and Wales were as a result of cardiovascular disease, with a quarter 
occurring before the age of 75, of which 70% were men (NICE, 2014). 
How many of the deaths in under 75 year olds, from CVD in England and Wales in 2010, were men? 
Question 3 
The estimated cost of CVD to the NHS was estimated to be 6,940 million in 2003, increasing to 7880 
million in 2010. If the cost continues to increase at the same rate, was is the likely cost in 2017? Round 
percentages up or down to nearest whole number 
Question 4 
Karen, a 49 year old receptionist, has a non-HDL cholesterol concentration of 7.0 mmol/litre and has 
been taking high-intensity statins for 12 weeks. NICE (2014) recommend that a greater than 40% 
reduction in non-HDL cholesterol should be aimed for at 3 months of treatment with high-intensity 
statin treatment.  
What would the maximum non-HDL cholesterol concentration be for Karen’s treatment to be deemed 
successful? 
Question 5 
Brian, a 50 year old builder, has a confirmed diagnosis of CVD and is commenced on Atorvastatin 80mg 
once daily. The treatment is available as a 28 tablet pack (£28.21) or 90 tablet pack (£90.67). If 
treatment is prescribed to cover the period from 1st January to June 30th (assume it is not a leap year), 
what is the price difference between the most expensive and least expensive of the prescribing 
options below? Do not split packs. 
Option 1: 2 x 90 tabs + 1 x 28 tabs 
Option 2: 1 x 90 tabs + 4 x 28 tabs 
Option 3:  7 x 28 tabs  
 
Answers 
Question 1 
(i) 19% = 19 in 100  
19 x 10 = 190 in 1000  
(ii) No of days 1st June to 30th Nov = 183 
Options 1: 1 x 90 tabs + 4 x 28 tabs = 1 x £79.20 + 4 x £ 24.64 (£98.56) = £177.76 
Option 2: 2 x 90 tabs + 1 x 28tabs = 2 x 79.20 (£158.40) + 1 x £24.64 = £183.04 
Option 3: 7 x 28tabs = 7 x £24.64 = £172.48 
Option 3 is the most cost effective 
 
Question 2 
(i) Total deaths = 180,000.  
One quarter = 180,000 ÷ 4 + 45,000 
1% of 45,000 = 450 
70% = 450 x 70 = 31,500 men 
 
Question 3 
Rate of increase between 2003 and 2010 = 940 million  
As a percentage of initial cost = 6940 million ÷ 940 million = 7% increase 
7% of 7880 million = 552 million  
7880 million + 552 million = 8,432 million 
 
Question 4 
100% = 7.0 
1% = 7 ÷ 100 = 0.07 
40% = 40 x 0.07 = 2.8 
7 – 2.8 = 4.2 mmol/litre 
 Question 5 
(i) Total days = 181 
Option 1: 2 x 90 tabs + 1 x 28 tabs = 2 x 90.67 (181.34) + 28.21 = £209.55 
Option 2: 1 x 90 tabs + 4 x 28 tabs = 90.67 + 4 x 28.21 (112.84) = £203.51 
Option 3:  7 x 28 = 7 x 28.21 = £197.47 
Difference: 209.55 – 197.47 = £12.08 
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